File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1002/(SICI)1099-1069(199603)14:1<1::AID-HON555>3.0.CO;2-Y
- Scopus: eid_2-s2.0-0029870630
- PMID: 8613131
- WOS: WOS:A1996UG62000001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Aggressive non-Hodgkin's lymphoma: T-cell versus B-cell
Title | Aggressive non-Hodgkin's lymphoma: T-cell versus B-cell |
---|---|
Authors | |
Keywords | Non-Hodgkin's lymphoma Prognostic factors T-immunophenotype |
Issue Date | 1996 |
Publisher | John Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182 |
Citation | Hematological Oncology, 1996, v. 14 n. 1, p. 1-6 How to Cite? |
Abstract | This study aimed to define the clinical characteristics, treatment outcome and independent prognostic factors of 144 patients with T- and 357 B-cell non-Hodgkin's lymphomas. Entities with well-defined immunophenotype and clinical characteristics were excluded. Patients with T-cell tumours were younger. T-immunophenotype was associated with more advanced disease and presence of B symptoms. They were also less likely to have bulky disease. Primary nasal lymphomas were usually T-cell while lymphomas arising from the gastrointestinal tract and Waldeyer's ring were mostly B-cell. On univariate analysis, T-immunophenotype was associated with lower CR rate, higher relapse rate and inferior overall survival. On the other hand, multivariate analysis revealed that advanced stage, presence of B symptoms, advanced age, high serum lactate dehydrogenase level and use of non-doxorubicin-containing regimens for induction were associated with poor prognosis. Immunophenotype was not a significant independent prognostic factor. |
Persistent Identifier | http://hdl.handle.net/10722/78225 |
ISSN | 2023 Impact Factor: 3.3 2023 SCImago Journal Rankings: 0.820 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Liang, R | en_HK |
dc.contributor.author | Todd, D | en_HK |
dc.contributor.author | Ho, FCS | en_HK |
dc.date.accessioned | 2010-09-06T07:40:32Z | - |
dc.date.available | 2010-09-06T07:40:32Z | - |
dc.date.issued | 1996 | en_HK |
dc.identifier.citation | Hematological Oncology, 1996, v. 14 n. 1, p. 1-6 | en_HK |
dc.identifier.issn | 0278-0232 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/78225 | - |
dc.description.abstract | This study aimed to define the clinical characteristics, treatment outcome and independent prognostic factors of 144 patients with T- and 357 B-cell non-Hodgkin's lymphomas. Entities with well-defined immunophenotype and clinical characteristics were excluded. Patients with T-cell tumours were younger. T-immunophenotype was associated with more advanced disease and presence of B symptoms. They were also less likely to have bulky disease. Primary nasal lymphomas were usually T-cell while lymphomas arising from the gastrointestinal tract and Waldeyer's ring were mostly B-cell. On univariate analysis, T-immunophenotype was associated with lower CR rate, higher relapse rate and inferior overall survival. On the other hand, multivariate analysis revealed that advanced stage, presence of B symptoms, advanced age, high serum lactate dehydrogenase level and use of non-doxorubicin-containing regimens for induction were associated with poor prognosis. Immunophenotype was not a significant independent prognostic factor. | en_HK |
dc.language | eng | en_HK |
dc.publisher | John Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182 | en_HK |
dc.relation.ispartof | Hematological Oncology | en_HK |
dc.rights | Hematological Oncology. Copyright © John Wiley & Sons Ltd. | en_HK |
dc.subject | Non-Hodgkin's lymphoma | - |
dc.subject | Prognostic factors | - |
dc.subject | T-immunophenotype | - |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | en_HK |
dc.subject.mesh | Female | en_HK |
dc.subject.mesh | Humans | en_HK |
dc.subject.mesh | Immunophenotyping | en_HK |
dc.subject.mesh | Lymphoma, B-Cell - drug therapy - immunology - pathology | en_HK |
dc.subject.mesh | Lymphoma, T-Cell - drug therapy - immunology - pathology | en_HK |
dc.subject.mesh | Male | en_HK |
dc.subject.mesh | Middle Aged | en_HK |
dc.subject.mesh | Prognosis | en_HK |
dc.subject.mesh | Treatment Outcome | en_HK |
dc.title | Aggressive non-Hodgkin's lymphoma: T-cell versus B-cell | en_HK |
dc.type | Article | en_HK |
dc.identifier.openurl | http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0278-0232&volume=14&spage=1&epage=6&date=1996&atitle=Aggressive+non-Hodgkin%27s+lymphoma:+T-cell+versus+B-cell | en_HK |
dc.identifier.email | Liang, R:rliang@hku.hk | en_HK |
dc.identifier.authority | Liang, R=rp00345 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1002/(SICI)1099-1069(199603)14:1<1::AID-HON555>3.0.CO;2-Y | en_HK |
dc.identifier.pmid | 8613131 | en_HK |
dc.identifier.scopus | eid_2-s2.0-0029870630 | en_HK |
dc.identifier.hkuros | 12326 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-0029870630&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 14 | en_HK |
dc.identifier.issue | 1 | en_HK |
dc.identifier.spage | 1 | en_HK |
dc.identifier.epage | 6 | en_HK |
dc.identifier.isi | WOS:A1996UG62000001 | - |
dc.publisher.place | United Kingdom | en_HK |
dc.identifier.scopusauthorid | Liang, R=26643224900 | en_HK |
dc.identifier.scopusauthorid | Todd, D=7201388182 | en_HK |
dc.identifier.scopusauthorid | Ho, FCS=7103408147 | en_HK |
dc.identifier.issnl | 0278-0232 | - |